Intervention Review

You have free access to this content

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV

  1. Mario Cruciani1,*,
  2. Carlo Mengoli2,
  3. Giovanni Serpelloni3,
  4. Saverio G Parisi2,
  5. Marina Malena4,
  6. Oliviero Bosco4

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 5 JUN 2013

Assessed as up-to-date: 10 JUL 2012

DOI: 10.1002/14651858.CD008270.pub2


How to Cite

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008270. DOI: 10.1002/14651858.CD008270.pub2.

Author Information

  1. 1

    ULSS 20 Verona, Center of Community Medicine and Infectious Diseases Service, Verona, Italy

  2. 2

    Università di Padova, Department of Histology, Microbiology and Medical Biotechnology, PADOVA, Italy

  3. 3

    ULSS 20 Verona, Dipartimento delle Dipendenze, 37135 Verona, Italy

  4. 4

    ULSS 20 Verona, Center of Community Medicine, 37135 Verona, Italy

*Mario Cruciani, Center of Community Medicine and Infectious Diseases Service, ULSS 20 Verona, Via Germania, 20, Verona, 37135, Italy. crucianimario@virgilio.it.

Publication History

  1. Publication Status: New
  2. Published Online: 5 JUN 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Bonjoch 2005 {published data only}
  • Bonjoch A, Paredes R, Galvez J. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005;39:313-6.
Clumeck 2001 {published data only}
  • Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S, CNA30017 Study Team. Simplification with ABC-based triple nucleoside therapy vs continued PI-based ART in HIV-1-infected patients with undetectable plasma HIV-1 RNA (CNA300017). AIDS 2001;15(12):1517-26.
Katlama 2003 {published data only}
  • Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, Lafeuillade A, Mamet JP, Beauvais L, AZL30002 European study team. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Medicine 2003;4(2):79-86.
Keiser 2005 {published data only}
  • Keiser PH, Sension MG, DeJesus E, et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis. 2005;5:2.
Maggiolo 2003 {published data only}
  • Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.. Clin Infect Dis 2003;37:41-9.
NEFA Study {published data only}
  • Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-46.
  • Martínez E, Arnaiz JA, Podzamczer D, et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.  AIDS. AIDS 2007;21:367-9.
  • Ochoa de Echaguen A, Arnedo M, Xercavins M, et al. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005;19:1385-91.
  •  Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19:917-25.
Opravil 2002 {published data only}
  • Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
Sprenger 2010 {published data only}
  • Sprenger HG, Langebeek N, Mulder PG, et al. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. AIDS Patient Care STDS 2010;24:361-6.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Abgrall 2006 {published data only}
  • Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS 2006;20:2099-106.
Abgrall 2007 {published data only}
  • Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.. Clin Infect Dis 2007;44:120-7.
Bommenel 2011 {published data only}
  • Bommenel T, Launay O, Meynard JL, et al. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. J Antimicrob Chemother 2011;66:1869-77.
Chiesa 2003 {published data only}
  • Chiesa E, Bini T, Adorni F, et al. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antiviral Therapy 203;8:27-35.
Cozzi-lepri 2006 {published data only}
  • Cozzi-Lepri A, De Luca A, Phillips AN, et al. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006;194:20-8.
Gulick 2004 {published data only}
Ibarra Barrueta 2004 {published data only}
  • Ibarra Barrueta O, Martínez Bengoechea MJ, Illaro Uranga A, Lertxundi Etxebarría U, Iglesias Lambarri A, Santos Ibáñez A. Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues [Simplificación con lamivudina, zidovudina y abacavir:repercusión sobre la adherencia, resultados clínicos e impacto económico]. Farmacia Hospitalaria 2004;28(Suppl. 1):27-33.
Kumar 2006 {published data only}
Kumar 2009 {published data only}
  • Kumar PN, Salvato P, Lamarca A, Dejesus E, Patel P, McClernon D, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther 2009;6:3.
Matheron 2003 {published data only}
  • Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, et al. CNA3007 Study Group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003;8:163-71.
Moyle 2002 {published data only}
  • Moyle G, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002;16(7):1086-7.
Munderi 2010 {published data only}
Orkin 2004 {published data only}
  • Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 2005;55:246-51.
Palma 2007 {published data only}
  • Palma P, Romiti ML, Cancrini C, et al. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.. AIDS 2007;21:465-72.
Staszewsky 2001 {published data only}
  • Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001;285(9):1155-63.
Vibhagool 2004 {published data only}
  • Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004;20(7):1103-14.
Wolbers 2007 {published data only}
  • Wolbers M, Opravil M, von Wyl V et al. Swiss HIV cohort study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS 2007;21:2201-7.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Arribas 2009
  • Arribas JR, Delgado R, Arranz A, Mun˜oz R, Portilla J, et al. Lopinavir-ritonavir monotherapyversus lopinavir-ritonavir and 2 nucleosidesfor maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009;51:147-52.
Bedimo
  • Bedimo R,   Westfall A,   Drechsler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. IAS 2009, Cape Town, 19-22 July 2009. 2009:Abst. MOAB202.
Brothers 2009
  • Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of Myocardial Infarction and Abacavir therapy: No increased risk across 52 Glaxo-Smith Kline-sponsored clinical trials in adult subjects. Journal of the Acquired Immune Deficiency Syndrome. 2009;51:20-8.
Bucher 2003
  • Bucher HC, Kofler A, Nüesch R, Young J, Battegay M, Opravil M. A Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.. AIDS 2003;17(17):2451-9.
Cruciani 2011
  • Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir Use and Cardiovascular Disease Events: a Meta-analysis of Published and unpublished Data. AIDS 2011;25:1993-2004.
DAD 2007
DAD 2008
  • D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-26.
DART 2006
  • DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48weeks in HIV-1-infected adults in Africa. AIDS. Jun 26 2006;20(10):1391-1399.. AIDS 2006;20:1391-9.
DHHS 2008
  • Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf November 23, 2008.
DHHS 2011
  • Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf January 2011.
Duvivier 2009
  • Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, ANRS 121 Hippocampe study group. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23:817-24.
EACS 2009
  • European AIDS Clinical Society. Guidelines. Clinical management and treatment of HIV infected Adults in Europe . http://www.europeanaidsclinicalsociety.org/guidelines.asp November 2009.
Egger 1997
Higgins 2003
Higgins 2008
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. The Cochrane Collaboration. Available from www.Cochrane-handbook.org 2008, issue updated February 2008.
Higgins 2009
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. [updated September 2008]. Available from www.cochrane-handbook.org 2009. The Cochrane Collaboration., 2009.
Higgins 2011
  • Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011., March 2011.
Katlama 2010
  • Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24:2365-74.
Kessler 2005
  • Kessler HA. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. Medscape General Medicine 2005;7(2):70.
Lambert-Niclot 2012
  • Lambert-Niclot, Flandre P, Valantin MA, Soulie C, Fourati, Wirden M, Sayon, Pakianather, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.. PLoS One 2012;7:e41390.
Lang 2009
  • Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, abstract 43LB, 2009.. 2009.
Lundgren 2009
  • Lundgren J, Reiss P, Worm S, et al. Risk of miocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: The D:A:D Study. Abstract of the 16th Conference on retrovirus and opportunistic Infection (CROI), Montreal, february 2009. Abst. 44LB. 2009.
Mallal 2008
Martínez 2003
  • Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-46.
Martínez 2007
Ochoa de Echanguen 2005
  • Ochoa de Echaguen A, Arnedo M, Xercavins M, et al. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005;19:1385-91.
Opravil 2004
  • Opravil M, Baumann D, Chaveb JP, et al. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy toabacavir, lamivudine, and zidovudine. AIDS 2004;18:2213-19.
Pappa 2008
  • Pappa K, Hernandez J, Ha B, et al. ABC/3TC shows robust virologic responses in ART-naive patients for baseline (BL) viral loads of >100,000c/mL and <100,000c/mL by endpoint used in ACTG5202. XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract THAB0304. 2008.
RevMan 2011
  • Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011., March 2011.
Ribaudo 2011
  • Ribaudo HJ, Benson CA, Zheng Y, et al. ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.. Clinical Infectious Diseases. 2011; Vol. 52:929-40.
Rizzardini 2006
  • Rizzardini G, Capetti A. Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review. Medical Science Monitor 2006;12(12):269-76.
Sax 2008
  • Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologic failure with ABC/3TC than TENOFOVIR/FTC in treatment-naive subjects with HIV RNA >100,000. XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract THAB0303. 2008.
SMART 2008
  • Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22(14):F17-24.
Smith 2008
  • Smith KY, Fine D, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TENOFOVIR/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT study. XVII International AIDS Conference (AIDS 2008). Mexico City. August 3-8, 2008. Abstract LBPE1138. 2008.
Valantin 2012
  • Valantin MA, Lambert-Niclot, Flandre P, Morand-Joubert L, Cabiè A, Meynard JL, Ponscarme D, Ajana F, Slama L, Curjol A, Cuzin L, Schneider L, Taburet AM, Marcelin AG, Katlama C, MONOI ANRS 136 Study Group. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.. J Antimicrob Chemother 2012;67:691-5.
Ware 1993
  • Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey manual and interpretation guide. Boston, Mass.: Nimrod Press, 1993.
WHO 2010
  • World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf 2010.
Worm 2010
  • Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30.
Wu 1997
 Fisac 2005
  •  Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19(917-25).